trending Market Intelligence /marketintelligence/en/news-insights/trending/xux4h5wr76zjxzztqdxnua2 content esgSubNav
In This List

Innate Immunotherapeutics changes name to Amplia Therapeutics

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Innate Immunotherapeutics changes name to Amplia Therapeutics

Innate Immunotherapeutics Ltd. is changing its name to Amplia Therapeutics Ltd.

The Australian pharmaceutical company will also change its stock code to ATX from IIL. Shareholders approved the changes at their annual general meeting in August.

The company said the changes are part of a wider branding refresh, as it focuses on therapeutic targets called focal adhesion kinase inhibitors. These can sensitize certain tumors to cancer drugs and chemotherapies.

Recently, the company found itself at the center of a U.S. congressman's insider trading scandal.